Evidence map›Paper›PMID 40025027›Full record

ArticleBlood cancer journal2025

Myeloid neoplasms with PHF6 mutations: context-dependent genomic and prognostic characterization in 176 informative cases.

Saubia Fathima, Ali Alsugair, Rong He, Abhishek A Mangaonkar, Kebede H Begna, Animesh Pardanani, Cinthya J Zepeda Mendoza, Kaaren K Reichard, Naseema Gangat, Ayalew Tefferi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Saubia FathimaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9979-7923
Ali AlsugairDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Rong HeDepartment of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-6116-8163
Abhishek A MangaonkarDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2458-9887
Kebede H BegnaDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0003-2730-8593
Animesh PardananiDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Cinthya J Zepeda MendozaDepartment of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.
Kaaren K ReichardDepartment of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0001-5439-0778
Naseema GangatDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-9104-6172
Ayalew TefferiDivision of Hematology, Mayo Clinic, Rochester, MN, USA. tefferi.ayalew@mayo.edu.ORCID 0000-0003-4605-3821

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent reports suggest a favorable prognosis for PHF6 mutation (PHF6

Indexed as

MutationMyelodysplastic SyndromesMyeloproliferative DisordersRepressor ProteinsRNA Splicing FactorsAdolescentAdultAgedAged, 80 and overFemaleHumansLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, ChronicMaleMiddle AgedPrognosisPHF6 protein, humanRepressor ProteinsRNA Splicing Factors

Identifiers

PMID40025027
PMCPMC11873042

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.